Compare · PFE vs SNY
PFE vs SNY
Side-by-side comparison of Pfizer Inc. (PFE) and Sanofi (SNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and SNY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $159.99B, about 1.4x SNY ($111.82B).
- Over the past year, PFE is up 8.5% and SNY is down 10.7% - PFE leads by 19.2 points.
- PFE has been more active in the news (15 items in the past 4 weeks vs 10 for SNY).
- Both have 25 recent analyst ratings on file.
- Company
- Pfizer Inc.
- Sanofi
- Price
- $28.07+0.88%
- $45.84+1.60%
- Market cap
- $159.99B
- $111.82B
- 1M return
- +12.30%
- +5.70%
- 1Y return
- +8.48%
- -10.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 15
- 10
- Recent ratings
- 25
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Latest PFE
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
- SEC Form 13F-HR filed by Pfizer Inc.
- Chairman & CEO Bourla Albert bought $1,000,920 worth of shares (38,000 units at $26.34), increasing direct ownership by 10% to 429,173 units (SEC Form 4)
- SVP & Controller Damico Jennifer B. sold $83,261 worth of shares (3,278 units at $25.40), decreasing direct ownership by 10% to 28,611 units (SEC Form 4)
- Director Blaylock Ronald E bought $998,821 worth of shares (39,231 units at $25.46), increasing direct ownership by 142% to 66,938 units (SEC Form 4)
- Director Buckley Mortimer J bought $960,369 worth of shares (37,632 units at $25.52) (SEC Form 4)
- NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off
- SEC Form 10-Q filed by Pfizer Inc.
- Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SNY
- Large owner Sanofi converted options into 672,778 shares (SEC Form 4)
- SEC Form 3 filed by new insider Sanofi
- Large owner Sanofi converted options into 782,855 shares and bought $5,100,000 worth of shares (300,000 units at $17.00) (SEC Form 4)
- SEC Form 6-K filed by Sanofi
- SEC Form 3 filed by new insider Sanofi
- SEC Form 6-K filed by Sanofi
- SEC Form 6-K filed by Sanofi
- SEC Form 13F-HR filed by Sanofi
- SEC Form 6-K filed by Sanofi
- FDA Approval for AVAPRO issued to SANOFI AVENTIS US